Is Fluticasone Propionate Superior to the Other Available Inhaled Steroids?

References

• Wenzel S E. Asthma as an inflammatory disease. Ann Allergy 1994; 72: 261–271
   PubMedGoogle Scholar
• Hegele R G, Hogg J C. The pathology of asthma: an inflammatory disorder. Severe Asthma: Pathogenesis and Clinical Management, S T Szefler, D YM Leung. Marcel Dekker Inc., New York 1995; 61–76
   Google Scholar
• Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, Sovijarvi A, Stenius-Aarniala B, Svahn T, Tammivaara R, Laitinen L A. Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–392
   PubMed Web of Science ®Google Scholar
• Van Essen-Zandvliet E E, Hughes M D, Waalkens H J, Duiverman E J, Pocock S J, Kerrebijn K F. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992; 146: 547–554
   PubMed Web of Science ®Google Scholar
• Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, Sovijarvi A, Stenius-Aarniala B, Svahn T, Tammivaara R, Laitinen L A. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700–705
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373–381
   PubMed Web of Science ®Google Scholar
• Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health. National Heart Lung and Blood Institute. 1997, NIH Publication No. 97–4051
   Google Scholar
• McCubbin M M, Milavetz G, Grandgeorge S, Weinberger M, Ahrens R, Sargent C, Vaughan L M. A bioassay for topical and systemic effect of three inhaled corticosteroids. Clin Pharmacol Titer 1995; 57: 455–460
   PubMedGoogle Scholar
• Phillips G H. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84((Suppl A))19–23
   PubMedGoogle Scholar
• Harding S M. The human pharmacology of fluticasone propionate. Respir Med 1990; 84((Suppl A))25–29
   PubMedGoogle Scholar
• Lipworth B J. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50: 105–110
   PubMedGoogle Scholar
• Dahl R, Lundback B, Malo J L, Mazza J A, Nieminen M M, Saarelainen P, Barnacle H. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993; 104: 1352–1358
   PubMed Web of Science ®Google Scholar
• Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 mg/day with inhaled beclomethasone dipropionate 400 mg/day in mild and moderate asthma. Arch Dis Child 1993; 69: 206–211
   PubMed Web of Science ®Google Scholar
• Kamada A K, Szefler S J. How should inhaled glucocorticoids be compared?. J Allergy Clin Immunol 1997; 99: 735–737
   PubMedGoogle Scholar
• Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol 1997; 99: 773–780
   PubMed Web of Science ®Google Scholar
• Noonan M, Chervinsky P, Busse W W, Weisberg S C, Pinnas J, DeBoisblanc B P, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152: 1467–1473
   PubMed Web of Science ®Google Scholar
• Hummel S, Lehtonen L. Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma. Lancet 1992; 340: 1483–1487
   PubMed Web of Science ®Google Scholar
• Levy M L, Stevenson C, Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 1996; 52: 1087–1092
   Google Scholar
• Booth H, Richmond I, Ward C, Gardiner P V, Harkawat R, Walters E H. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995; 152: 45–52
   PubMed Web of Science ®Google Scholar
• Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, Testi R, Foresi A. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo controlled study. Am J Respir Crit Care Med 1997; 155: 1864–1871
   PubMed Web of Science ®Google Scholar
• Trigg C J, Manoltsas N D, Wang J, Calderon M A, McAulay A, Jordan S E, Herdman M J, Jhalli N, Duddle J M, Hamilton S A, Devalia J L, Davies R J. Placebo controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994; 150: 17–22
   PubMed Web of Science ®Google Scholar
• Clark D J, Grove A, Cargill R I, Lipworth B J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 52: 262–266
   Google Scholar
• Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996; 9: 1427–1432
   PubMedGoogle Scholar
• Todd G, Dunlop K, McNaboe J, Ryan M F, Carson D, Shields M D. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996; 348: 27–29
   PubMed Web of Science ®Google Scholar
• Toogood J H. High-dose inhaled steroid therapy for asthma. J Allergy Clin Immunol 1989; 83: 528–536
   PubMed Web of Science ®Google Scholar